Skip to main content

Table 1 Association between baseline subject characteristics and HU: EU and Non-EU cohorts

From: Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study

Non-EU cohort

EU cohort

Baseline characteristic

C

Baseline characteristic

C

Age (years)

0.16

Age

0.34

Alcohol use (Yes)

−0.19

Alcohol use (Yes)

−1.03

Height (cm)

0.158*

Height (cm)

0.247

Weight (kg)

−0.115*

Weight (kg)

−0.385**

Country AU vs. US

−4.359*

Country BE vs. UK

−9.088*

Country CA vs. US

−0.570

Country NL vs. UK

−2.997

Country NZ vs. US

−1.056

Country SE vs. UK

−3.684

Smoke (Yes)

−5.204*

Smoke (Yes)

−8.712**

Prevalent vertebral fractures

−0.638

Prevalent vertebral fractures

−2.245**

Baseline femoral neck BMD (# of SDs < mean for females)

−0.885

Baseline femoral neck BMD (# of SDs < mean for females)

2.192

Number of preexisting conditions

−0.447***

Number of preexisting conditions

−1.434***

Number of ONF

−0.549

Number of ONF

0.751

Years postmenopausal

−0.095

Years postmenopausal

−0.305

Family history of osteoporosis (Yes)

−1.004

Family history of osteoporosis (Yes)

4.332

History of hysterectomy (Yes)

−0.008

History of hysterectomy (Yes)

−4.723*

Married (Yes)

−0.118

Married (Yes)

0.587

Years of education

0.347*

Years of education

0.370

Baseline LS BMD (# of SDs < mean for females)

0.472

Baseline LS BMD (# of SDs < mean for females)

−0.209

Variance explained

0.14

Variance explained

0.20

  1. Abbreviations: AU Australia, BMD Bone mineral density (score), BE Belgium, C Regression coefficient, CA Canada, EU European Union, LS Lumbar spine, NL Netherlands, Non-EU Non-European Union, NZ New Zealand, ONF Osteoporotic non-vertebral fractures, SD Standard deviation, SE Sweden, UK Great Britain, US United States.
  2. *p < 0.05, **p < 0.001, ***p < 0.0001.